Asahi Kasei Pharmaceuticals, a Japan-based drugs company, has acquired a company it had incubated before handing over to venture capital firms to develop as a way to share costs and risks in developing innovative molecules for potential therapies.
Asahi Kasei Pharmaceuticals, a Japan-based drugs company, has acquired a company it had incubated before handing over to venture capital firms to develop as a way to share costs and risks in developing innovative molecules for potential therapies.
Artisan Pharma, a US-based biotech company to treat people with blood poisoning, had originally been spun out of Asahi Kasei in 2006 with $39m in venture funding by NovaQuest (the corporate venturing unit of Quintiles), New Leaf Partners, NGN Capital,Jafco Ventures and…
